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Nasopharyngeal Pneumococcal 
Carriage in Nigeria: a two-site, 
population-based survey
Ifedayo M. O. Adetifa  1,2,3, Aishatu L. Adamu  4, Angela Karani2, Michael Waithaka2,  
Kofo A. Odeyemi5, Christy A. N. Okoromah3, Mohammed M. Bello4, Isa S. Abubakar4,  
Victor Inem5 & J. Anthony. G. Scott  1,2
Changes in nasopharyngeal (NP) carriage of vaccine-type (VT) Streptococcus pneumoniae can be 
used to assess the effectiveness of a pneumococcal conjugate vaccine (PCV10). We conducted a 
baseline carriage survey in rural (Kumbotso, Kano) and urban (Pakoto, Ogun) Nigeria. In this cross-
sectional study, we obtained data on demography, clinical history, risk factors, and took NP swabs for 
pneumococcal culture. We calculated crude and age-standardised carriage prevalence and used log-
binomial regression to assess risk factors for carriage. Among children aged <5 years, 92% (95% CI: 
88–95%) and 78% (73–82%), respectively, carried any pneumococcus and 48% and 50%, respectively, 
carried PCV10 serotypes. In Kumbotso, carriage prevalence was >40% across all ages. The age-
standardized prevalence of pneumococcal carriage was 66% in Kumbotso and 40% in Pakoto. The 
most commonly identified serotypes were 19 F, 6 A and 23 F. Risk factors for carriage were young age, 
recent rhinorrhoea, cohabitation with ≥2 children aged <5 years, and sharing a bed with ≥2 persons. 
Pneumococcal carriage prevalence is high in this Nigerian population. Persisting prevalence of VT-
carriage in older children and adults suggests that PCV10 introduction in children will not eliminate 
transmission of vaccine serotypes rapidly. High vaccine coverage will therefore be required to ensure full 
protection of children.
Pneumococcal conjugate vaccines (PCVs), first introduced in high income countries, have substantially reduced 
the burden of invasive pneumococcal diseases (IPD) and pneumonia1. PCV introductions in Africa have had 
varied but significant direct and indirect effects on IPD2,3 and pneumonia4 caused by vaccine type (VT) serotypes. 
PCVs have reduced the carriage prevalence of VT serotypes in both the vaccinated and unvaccinated5,6.
With ~6.7 million cases causing >100,000 deaths per annum, Nigeria has the highest estimated burden of 
childhood pneumococcal diseases in Africa7,8. So, Nigeria commenced a phased introduction of a 10-valent PCV 
(PCV10) in 2015 that attained nationwide spread in 2016. Gavi, The Vaccine Alliance made this possible by sup-
plying PCV to Nigeria and other eligible countries at less than a tenth of the purchase price9. However, Nigeria 
like many other African countries, has not invested in the longitudinal surveillance systems required to determine 
effectiveness of the PCV immunisation programme and provide an evidence base to sustain this investment2,3,6.
Although Gavi has supported introductions of new vaccines, there is an associated risk to sustainability of pro-
grammes with expensive new vaccines like PCV. For example, with Nigeria in the accelerated phase of transition 
from Gavi support, current subsidy will drop from $199 million in 2017 to $74 million in 2021. Concurrently, 
the country’s commitment to vaccine purchase will rise >2-fold from $123 million $279 million from 2017 to 
2021. Therefore, the need to generate context-specific vaccine effectiveness and cost effectiveness data to support 
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the case for continued investment in these vaccines at the end of this transition cannot be over emphasised. 
Unfortunately, establishing IPD surveillance is not just late but too expensive and impracticable at this point.
Carriage is on the causal pathway to disease, and is also a reflection of transmission10. So, changes in 
VT-carriage prevalence can be used to examine the impact of vaccine on transmission and to estimate the likely 
changes in disease risk, through modelling. The modelling methods developed to predict PCV10 effectiveness 
against disease by studying changes to NP carriage of VT-pneumococci vary and are attractive alternatives to 
IPD data because they do not require expensive surveillance systems. They utilise a mixture of pre-vaccine 
serotype-specific IPD incidence and carriage, population mixing patterns, serotype specific case-to-carrier ratios, 
post-vaccine carriage data, etc., to determine vaccine effectiveness11–16. Although an emerging area of research 
especially in low-income settings with high disease burden, we and others have validated some of these modelling 
approaches using observed carriage and IPD data11,16 and there is merit in expanding their application in these 
settings.
As part of a plan to assess PCV10 impact using serial pneumococci carriage data, we conducted baseline 
cross-sectional surveys of NP carriage in two sites-one each in northern and south-western Nigeria. We had 
previously studied the south-western site (Pakoto) so it will provide a more stable estimate of baseline prevalence.
Methods
We studied two centres in Nigeria, one urban (Pakoto, Ogun State) and one rural (Kumbotso, Kano State). 
The methods followed those of a previous study conducted in Pakoto in March 200917. We defined the study 
areas based on a single reference point: for Pakoto this was the Lagos University Teaching Hospital (LUTH) 
Primary Health Care and Rural Medicine; for Kumbotso it was the Aminu Kano Teaching Hospital (AKTH) 
Comprehensive Primary Health Care Centre. All residents living within 10 km of these reference points were 
eligible for inclusion in the study. The LUTH centre serves communities spread across Ifo and Ado-Odo/Ota 
Local Government Areas (LGA) ~40 km away from Lagos, with population densities of 1007/ km2 and 600/km2, 
respectively. AKTH serves Kumbotso LGA ~22 km from Kano, with a population density of 1873/km2.
A sampling frame was not available for both study sites; we therefore sampled the population based on volun-
tary participation. Following community consultation, sensitisation of community leaders and announcements 
by town criers, the study team set-up a research base on pre-agreed dates at pre-selected locations. We then 
sampled all eligible members of the community who came to the study site until either the target sample size was 
achieved or the pre-determined period for field activities came to an end. We selected a sample size of 1000 per 
site to estimate carriage prevalence with adequate precision for the least prevalent VT serotype (0.38% based on 
results from earlier survey17): for example, the 95% Confidence Intervals (CI) for an estimate of 0.4% prevalence 
would be 0.1–1.0)
The study was conducted at Kumbotso in December 2016 and at Pakoto in February 2017. These selected 
study sites were part of the last phase of PCV10 (Synflorix®) introduction. Kumbotso began PCV10 vaccinations 
in July 2016 and Pakoto in October 2016. WHO/ UNICEF and administrative reports put national coverage of 
the 3rd dose of PCV10 at 13% and 73% respectively in 201518. At the time of sampling, infants had only recently 
become eligible for vaccination because Kumbotso and Pakoto had experienced just 5 and 4 months respectively 
of PCV10 introduction. Only 6.5% (41 of 630) of children <5 years had vaccine records and only 12% (5 of 41) 
had received 2 or more doses of PCV10.
Questionnaires administered in a language understood by all consenting participants were used to obtain 
data on sex, age, household size and composition; education, occupation, history of oral antibiotic treatment and 
respiratory symptoms in the two weeks preceding the study.
Following World Health Organisation guidelines, we obtained nasopharyngeal specimens from all consenting 
study participants using nylon-tipped flexible nasopharyngeal flocked swabs (Copan flock technologies, Cat. No. 
503CS01, Brescia, Italy)19. Following sampling, nasopharyngeal swab tips were immediately immersed in skim 
milk tryptone glucose glycerol (STGG) transport media. In Kumbotso, samples were transported within 8 hours 
of collection respectively to the AKTH Microbiology Laboratory, Kano while for Pakoto, they were transported 
to and stored at the Covenant University Health Centre laboratories, Sango Ota till the end of fieldwork following 
which they were moved to the Central Research Laboratory, College of Medicine University of Lagos, Lagos. In 
these locations, the STGG samples were frozen at −200C till they were shipped on dry ice to the microbiology 
laboratory at KEMRI-Wellcome Trust Research Programme (KWTRP), Kilifi, Kenya for processing19. Samples 
from Kumbotso were stored in country for 8 weeks and those from Pakoto for 6.5 weeks.
S. pneumoniae isolates were identified from gentamicin-blood agar by optochin susceptibility testing; sero-
typing was done by latex agglutination and the Quellung reaction (including specific antisera for all members 
of serogroup 6). Where colonies varying in appearance were seen, the dominant morphotype was serotyped. In 
case of optochin intermediate susceptibility, bile solubility was used for confirmation. Where Quellung reaction 
was inconclusive, suspected pneumococci were tested by polymerase chain reaction (PCR) targeting the genes 
encoding autolysin (lytA). If lytA-positive, the isolates were then serotyped using multiplex PCR20.
Statistical analyses were performed using Stata 13.1 (Stata Corp LP, College Station, Texas). The main outcome 
variable was overall, vaccine type and location-specific nasopharyngeal carriage prevalence and associated 95% 
confidence intervals (95% CI). Vaccine serotypes were defined for the following vaccines; Synflorix® PCV10 (1, 
4, 5, 6 B, 7 F, 9 V, 14, 18 C, 19 F, and 23 F), Prevnar 13® PCV13 (PCV10 + 3, 6 A, 19 A) and a PCV10 (SII), a variant 
by Serum Institute India (1, 5, 6 A, 6 B, 7 F, 9 V, 14, 19 A, 19 F and 23 F) currently in clinical development. Carriage 
prevalence was also estimated across the following age-strata: 0–4, 5–17, 18–34, 35–49 and ≥50 years. To adjust 
for differing age structure by study location, carriage prevalence were age-standardised using the age strata for 
INDEPTH network’s standard population for low- and middle income countries as weights21.
We examined associations between risk factors and carriage by estimating relative risk. Risk factors examined 
were age, sex, household smoking, household cooking fuel, number of under-five year-olds in the household, 
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number of persons sharing a bed, history of upper respiratory tract infection and antibiotic use in the preceding 
2 weeks. We tested the association between the distribution of participant characteristics of interest and the study 
locations with chi squared tests. Adjusted prevalence ratios were calculated with log-binomial regression models. 
Where these failed to converge, Poisson regression models with robust 95%CIs were used instead. Prevalence 
ratios were adjusted for all potential confounding variables that were significant at a p-value <0.05.
The study was approved by the following: London School of Hygiene and Tropical Medicine Ethics Committee, 
Kenya Medical Research Institute’s Scientific and Ethical Review Unit, Research and Ethics Committees of Aminu 
Kano and Lagos University Teaching Hospitals, and by the Kano State Ministry of Health. All study procedures 
including laboratory methods were performed in accordance with the relevant guidelines and regulations. 
Parents/guardians of minors and every adult participant gave written informed consent before participation in 
study. Participants aged 15–17 years gave written assent in addition to the written consent given by parents/
guardians.
Data availability statement. This is an ongoing study so data is not publicly available. However, data can be 
made available from the KWTRP Institutional Data Governance Committee to researchers who meet the criteria for 
access to data. Interested researchers can contact, Ms. Elizabeth Mwatata (EMwatata@kemri-wellcome.org).
Results
General characteristics of the study population. The epidemiological characteristics of participant 
overall and by location are shown in Table 1. There were more females, household crowding, more upper res-
piratory symptoms and greater reliance on firewood for cooking in the rural population (Kumbotso) and greater 
access to antibiotics and flush toilets in the urban population (Pakoto).
Carriage Prevalence. Out of 1800 participants, 1109 [61.6% (95% CI: 59.3–63.9)] were found to be carry-
ing pneumococci. The crude carriage prevalence in Kumbotso, 73.7% (95% CI: 70.7–76.6) was higher than seen 
in Pakoto, 50.1% (95% CI: 46.8–53.4). As shown in Table 2, crude prevalence was highest for the youngest age 
groups in each site and was higher at all ages in Kumbotso than in Pakoto. Although carriage declined sharply at 
both sites from approximately 18 years onwards, the persistence of high carriage prevalence at older age groups 
was particularly noticeable in Kumbotso. We observed a marked association between carriage and sex in Pakoto 
(58.2% (95% CI: 53.3–63.2) in males compared to 43.9% (95% CI: 39.7–48.2) in females) but little difference in 
Kumbotso (males 76.7% compared to females 72.1%). Similar to the crude estimates, age-standardised carriage 
prevalence in Kumbotso was higher than in Pakoto (65.7% [95% CI: 55.9–75.2] vs. 40.2% [95% CI: 30.3–50.3]).
Pneumococci Serotypes in carriage and proportions included in PCVs. The 1109 pneumococci 
isolates found represented 65 different serotypes and 47 (4.0%) of the isolates were non-typeable (NT). Fifty-eight 
and 48 different serotypes were seen in Kumbotso and Pakoto, respectively, and the prevalence of each serotype 
in rank order by location is shown in Figs 1 and 2. The collection of isolates was dominated by vaccine serotypes. 
No serotype 6 C was found and there were only 2 (0.3%) and 1 (0.2%) isolates of serotypes 1 and 5, respectively. 
There were some differences in serotype-specific prevalence by age and study location but the patterns observed 
for children aged <5 years in both locations were similar (see Table S1).
Carriage prevalence of serotypes contained in PCVs by location and age group can be seen in Table 3. The 
proportion of PCV10 (Synflorix®) serotypes carried by participants was slightly higher in Pakoto than Kumbotso 
for all age categories. In addition, a higher proportion of participants carried serotypes found in PCV10 (SII) 
compared to Synflorix®. Regardless of PCV formulation, carriage prevalence of vaccine serotypes was highest 
the youngest age categories.
Assessment of risk factors for carriage. In univariate analyses, age <35 years, being male, residence in a 
rural study site (Kumbotso), a recent history of a cough and runny nose, living in households with 1 or more chil-
dren under-fives, sharing a bed with ≥2 persons and the use of firewood as the main cooking fuel, were all associ-
ated with carriage (Table 4). In multivariate analyses, we tested for interactions between sex and location because 
of the earlier described association between gender, settlement and carriage. The following were associated with 
carriage: age <18 years, residence in Kumbotso, recent history of a runny nose, living in a household with ≥2 
children aged under 5 years, and sharing a bed with ≥2 persons in a household (Table 4). Of all of the age groups 
below 18 years, carriage prevalence in the 0–4-year-olds was the highest (2.3 times that in oldest age group). There 
was no interaction between sex and study location (RR 0.83 [95%CI 0.64–1.01], p = 0.13 for Likelihood ratio test).
Discussion
Given the estimated burden of pneumococcal diseases in Nigeria7,8, there is a dearth of clinical surveillance data 
in the country. This dearth of data extends to local carriage data22–24.
This study was conducted in anticipation of using changes in NP carriage of pneumococci observed in serial 
surveys to assess the effectiveness of the PCV10 immunisation programme. Having anticipated the introduc-
tion of a PCV and knowing it was impractical and expensive to commence IPD surveillance, we had earlier 
acquired pre-vaccine carriage data and described the population biology of carried pneumococci in southwestern 
Nigeria17. We now report on a second baseline survey with expanded scope to a second study site based in north-
ern Nigeria and anticipate producing estimates of impact on disease once we have a significant ‘post-vaccine’ 
survey.
We found crude pneumococcal carriage prevalence in both rural and urban study locations and across all 
age groups was high. The very high carriage prevalence in children aged <5 years in Kumbotso (rural) is con-
sistent with findings in similar settings in Gambia25–27 and Ethiopia28,29 and most likely reflects the intensity of 
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transmission/the force of infection in these settings. However, it higher than that seen in rural Kenya6,30 and in 
ethnic minorities resident in similarly deprived/underserved areas31,32.
For comparability between populations with different population structures, we calculated age-standardised 
carriage prevalence. The age-standardised carriage was much higher in our rural northern Nigeria location than 
in a rural Kenyan setting6, than in combined studies from West Africa and the rest of sub-Saharan Africa33. They 
also exceed the 44.4% reported by Hansman in Ibadan, South West Nigeria in 197722, and the 69% recorded 
Characteristics*
Location
p-value for difference**
Kumbotso (rural) Pakoto (urban)
N % N %
Sample size 876 48.7 924 51.3
Sex <0.0005
Female 548 62.6 521 56.4
Age group (years) <0.0005
 0–4 295 33.9 335 36.5
 5–17 288 33.1 250 27.2
 18–34 145 16.7 109 11.9
 35–49 76 8.7 84 9.1
 ≥50 66 7.6 141 15.3
Clinical history (in preceding 2 weeks)
 Cough 448 51.1 216 23.4 <0.0005
 Rhinorrhoea 712 81.3 238 25.8 <0.0005
 Antibiotic use 65 7.4 145 15.7 <0.0005
Main cooking fuel <0.0005
 Firewood 828 94.5 40 4.3
 Kerosene 16 1.8 515 55.7
 Cooking gas 12 1.4 326 35.3
Household amenities
 Main source of drinking water NS
 Piped water 789 90.1 818 88.5
 Dug well 74 8.5 73 7.9
 Main means of sewage disposal <0.0005
 Flush/pour flush toilet 89 10.2 777 84.1
 Pit latrine 756 86.3 140 15.2
Household composition
Have ≥2 children <5 years in 
household 643 73.4 95 10.3 <0.0005
Have ≥2 sharing a bed 727 83.0 185 20.1 <0.0005
Tobacco exposure
Smoker (if aged ≥12 years) 9 2.6 5 1.3 NS
Smoker in the household 65 7.4 20 2.2 <0.0005
Table 1. General Characteristics of the Nigerian pneumococcal carriage survey population. *Subtotals for 
characteristics may not add up to N on account of missing data. **p-values are for differences in group-level 
characteristics between locations unless individual level values are provided.
Kumbotso (rural) Pakoto (urban)
Male Female Male Female
N % N % N % N %
Age group*
All ages 250 76.7 395 72.1 219 58.2 229 44.0
0–4 years 131 91.6 139 92.1 132 77.2 117 78.0
5–17 years 95 75.4 133 82.1 70 53.4 51 46.4
18–34 years 11 39.3 66 56.4 2 25.0 25 25.0
35–49 years 4 57.1 30 43.5 5 31.3 14 20.6
≥50 years 9 40.9 24 54.6 9 19.2 21 23.1
Table 2. Crude carriage prevalence in study locations by age and sex. *Subgroup subtotals may not add up to 
‘Ns’ because of missing data (3 females for Kumbotso and 1 each for males and females in Pakoto have missing 
age data).
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recently in infants in south eastern Nigeria23. The age-standardised carriage prevalence here also validates the 
age-standardised results of our earlier survey conducted in the same season, and urban location-Pakoto (40.2% 
now vs. 37.0 previously). In addition, crude PCV10 serotype coverage also remained stable between both surveys 
in this location (43.8% vs. 44.5% respectively)17.
Almost half of study population aged ≥ 5 years carried pneumococci which is significant especially as the 
crude carriage prevalence for the 5–17-year-olds, a third of our study population, ranged from 49.2–79.2%. Social 
contact data in similar settings of high transmission show children <5 years have the highest daily contacts across 
all ages34 and that household transmission of pneumococci is mostly from older to younger children35. Taken 
Figure 1. Nasopharyngeal carriage prevalence of individual Pneumococcal serotypes in Kumbotso (rural 
setting), Nigeria.
Figure 2. Nasopharyngeal carriage prevalence of individual Pneumococcal serotypes in Pakoto (urban setting), 
Nigeria.
Location Kumbotso (rural) Pakoto (urban)
Vaccine 
preparation N
PCV10 PCV10 (SII) PCV13
N
PCV10 PCV10 (SII) PCV13
% % % % % %
Age group
0–4 years 271 48 61 68 260 50 65 69
5–17 years 228 31 35 48 123 41 50 58
18–34 years 77 26 25 35 27 33 37 44
35–49 years 34 27 27 35 19 32 32 42
≥50 years 33 6 12 21 32 25 28 56
Table 3. Carriage Prevalence of Vaccine-Type Serotypes by location and by age-group.
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together with our results, these suggest the older age groups, particularly the 5–17-year-olds, may serve as reser-
voirs that will facilitate transmission of VT-pneumococci to susceptible under-fives as seen even in the vaccine 
era6. Therefore, with higher carriage prevalence in children <5 years, the well-known challenges of attaining 
high vaccination coverage in Nigeria and the fact that vaccine effects may take 3–4 years to become apparent at 
high coverage2, it is unlikely the PCV10 progammme can achieve near elimination of VT pneumococci in car-
riage as seen elsewhere36. Crude carriage in adults, 35.8% (range 23.4 −50.2%) is similar to reports from Nigeria 
(15–25-year- olds)24, Gambia25 but higher than observed in the rest of sub-Saharan Africa33.
The differences in the study setting for each of the Nigerian studies is most likely an important contributor to 
the difference in results. Furthermore, our study was conducted during the Harmattan season. This cold season 
runs from the end of November into the middle of March and gets its name from a dry and dusty northeasterly 
trade wind that blows from the Sahara Desert in a south-westward direction to the Gulf of Guinea37,38. Kumbotso 
within Nigeria’s Sahel Savannah endures a greater share of this weather front compared to Pakoto or any other 
location further south. This season is also associated with increased pharyngeal carriage of Neisseria meningitidis 
and meningitis outbreaks in the meningitis belt of Africa within which Kumbotso in Kano State falls39,40. Some of 
the risk factors that were strongly associated with carriage were also rarely found in the urban areas and this may 
also explain the higher prevalence of carriage in the rural area.
Characteristic n/N* %
Pneumococcal carriage- Prevalence Ratios (95% CI)
Univariate analysis Multivariable analysis†
Overall p-value Overall p-value
Age group (years)
≥50 65/207 31.4 1.00 1.00
35–49 53/160 33.1 1.06 (0.78–1.42) 0.726 0.96 (0.71–1.30) 0.788
18–34 104/254 40.9 1.30 (1.02–1.67) 0.037 1.14 (0.88–1.47) 0.324
5–17 351/538 65.2 2.08 (1.68–2.57) <0.0005 1.79 (1.44–2.23) <0.0005
0–4 532/630 84.3 2.68 (2.19–3.29) <0.0005 2.26 (1.82–2.81) <0.0005
Settlement
Pakoto 463/924 50.1 1.00 1.00
Kumbotso 646/876 73.7 1.50 (1.36–1.58) <0.0005 1.40 (1.11–1.65) <0.0005
Sex
Male 469/702 66.8 1.00 1.00
Female 624/1069 58.4 0.87 (0.81–0.94) <0.0005 1.02 (0.95–1.09) 0.58
Runny nose in the preceding 2 weeks
No 416/838 49.6 1.00 1.00
Yes 687/950 72.3 1.46 (1.35–1.58) <0.0005 1.13 (1.02–1.25) 0.018
Cough in the preceding 2 weeks
No 622/1125 55.3 1.00 1.00
Yes 482/664 72.6 1.31 (1.2–1.41) <0.0005 0.98 (0.91–1.06) 0.656
Antibiotics use in the preceding 2 weeks
No 964/1567 61.5 1.00
Yes 135/210 64.3 1.05 (0.94–1.16) 0.425
Number of<5 years residents in household
0 282/607 46.5 1.00 1.00
1 264/428 61.7 1.33 (1.19–1.49) <0.0005 1.09 (0.97–1.22) 0.157
≥2 552/738 74.8 1.61 (1.46–1.77) <0.0005 1.15 (1.02–1.30) 0.028
Number of persons sharing a bed
0–1 425/863 49.3 1.00 1.00
2 487/662 73.6 1.49 (1.38–1.62) <0.0005 1.12 (1.01–1.24) 0.034
≥3 191/250 76.4 1.55 (1.41–1.71) <0.0005 1.15 (1.02–1.29) 0.019
Exposure to cigarette smoking
No 1047/1703 61.5 1.00
Yes 56/85 65.9 1.07 (0.92–1.25) 0.390
Main household cooking fuel
Gas 160/338 47.3 1.00 1.00
Kerosene 283/531 53.3 1.13 (0.98–1.29) 0.092 1.09 (0.96–1.24) 0.201
Firewood 627/868 72.2 1.53 (1.35–1.72) <0.0001 0.90 (0.74–1.10) 0.315
Others (Charcoal, 
sawdust, crop) 15/24 62.5 1.32 (0.95–1.84) 0.137 1.26 (0.96–1.65) 0.093
Table 4. Risk factors for pneumococcal carriage across all ages in Nigerian populations. †Results of a Poisson 
model with robust 95% CI are presented. *N may differ from total sample size 1800 because of missing data.
www.nature.com/scientificreports/
7SCIEnTIfIC REPORTS |  (2018) 8:3509  | DOI:10.1038/s41598-018-21837-5
In this one study, we found 65 pneumococcal serotypes similar to the 70 identified in review of studies in 
sub-Saharan Africa33. This expands our understanding of the diversity of prevalent pneumococci in carriage in 
Nigeria. Despite expanded testing for serogroup 6 serotypes, we did not find any pneumococci of serotype C. 
This is consistent with our earlier survey. Serotypes 1 and 5 are commonly isolated in disease in Africa41–44 where 
they cause about 13% and 10% of meningitis and other IPD respectively45. However, we found carriage of these 
serotypes was very low in our study population similar to other reports17,25,30,44.
Unfortunately, data on serotypes responsible for IPD in Nigeria46–48 are also very limited. Pooled data from 
Africa (>90% southern Africa studies) show the top ranked serotypes responsible for childhood IPD are 14, 6B, 
6 A, 23 F, 19 F and 19 A45. PCV10 covers serotypes responsible for 62% and 67% of meningitis and other IPD 
respectively, while it is 72% and 81% for these conditions respectively for PCV1345. That the proportion of sero-
type covered is this high for IPD compared to carriage is not surprising as both vaccines significantly reduce the 
incidence of VT-IPD2,3,11,49, pneumonia4 and VT-carriage6,50 in vaccinated and unvaccinated children. Estimating 
the full extent PCV impact on IPD with carriage data is challenging because relative to IPD, VT-serotypes are less 
represented in carriage especially serotypes 1 and 519,51. Therefore, some caution will be required if unadjusted 
carriage data is used for assessments of impact of introducing PCVs introduction and in particular for PCVs 
serotype-specific comparisons. However, studies such as ours are essential to provide information about serotype 
changes and potential impact on changing epidemiology in a relatively inexpensive manner, and to inform future 
vaccine development.
In theory, there would be a greater impact for PCV(SII) and PCV13 against IPD compared to Synflorix® 
based on carriage data but there are also other considerations. For example, an expanded impact on IPD medi-
ated by induction of cross protection against vaccine-related serotypes- 6 A and 19 A has been attributed to 
Synflorix® 52,53. However, our carriage data in Kenya6 suggests otherwise. In addition, PCV13 despite containing 
serotype 3 is thought to confer very little or no protection against this serotype54. In contrast, surveillance data 
from The Gambia shows a decline and subsequent elimination of serotype 3 IPD following PCV13 introduction3. 
Despite the foregoing, the overall impact of vaccination against IPD is similar irrespective of PCV-type. This 
underpins the current consensus to prioritise PCV introductions in all settings and especially in those with the 
highest under-5 mortality, and to ensure high vaccination coverage1,54,55.
The main risk factors for carriage in this survey were young age (<18 years), history of rhinorrhoea, rural 
residence, living in household with ≥2 children aged <5years and sharing a bed with ≥2 persons. These are all 
well described risk factors for carriage17,31.
Obtaining a randomly selected population sample in Nigeria is a major challenge in research and this 
explains why only a few have succeeded in doing this in the past. That our sampling of participants was not 
probability-based is the principal limitation of this study. Although young children are the usual focus of carriage 
studies, another limitation was the small numbers of adult male participants compared to their female counter-
parts. Considering our participants were volunteers (not induced by payments) responding to communication 
via community leaders and town criers, and were healthy and/or ambulatory, any selection bias is likely to lead 
to an underestimate of carriage prevalence. Since the extent to which biases present in these study locations may 
change overtime is unknown, we will explore the use of satellite photos and other options to create suitable sam-
pling frames that will allow for random sampling in follow-up surveys.
Conclusions
Pneumococcal carriage is highly prevalent in the age group targeted for vaccination. The high carriage prevalence 
seen in the older age groups suggests the probability of eliminating carriage of VT serotypes in the population by 
vaccinating birth cohorts alone (as happened in the USA) is very low. Therefore, the indirect benefits of vaccine 
are likely to be limited – and the benefits of the vaccine programme will be in proportion to the vaccine uptake, 
which is quite poor in Nigeria. Priority should be given to ensuring high vaccination coverage in this setting. 
These findings highlight the importance of these carriage data - and their future complements - to test and inform 
policy in PCV10 in Nigeria.
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